AGPCNP ANCC EXAM AND PRACTICE EXAM
TEST BANK | ANCC ADULT GERONTOLOGY
PRIMARY CARE NURSE PRACTITIONER
QUESTIONS AND CORRECT ANSWERS
(VERIFIED ANSWERS) PLUS RATIONALES
2025/2026 Q&A | INSTANT DOWNLOAD PDF
Core Domains:
• Health Promotion, Screening, and Disease Prevention
• Advanced Pathophysiology and Clinical Assessment
• Differential Diagnosis and Clinical Decision-Making
• Pharmacology and Medication Management
• Chronic Disease Management (Cardiovascular, Pulmonary, Endocrine,
Neurologic, Renal)
• Acute and Episodic Care
• Geriatric Syndromes and Frailty
• Professional Role, Ethics, and Healthcare Systems
• Cultural Competence and Health Equity
• Evidence-Based Practice and Quality Improvement
Introduction
,The AGPCNP ANCC (Adult-Gerontology Primary Care Nurse Practitioner)
certification examination is a rigorous assessment designed to validate the clinical
knowledge, critical thinking, and evidence-based decision-making skills required for
advanced practice nursing with young adult, adult, and older adult populations. This
comprehensive practice exam mirrors the content, format, and cognitive complexity
of the actual ANCC AGPCNP-BC board certification examination. The test bank
covers all major domains: health promotion and disease prevention; advanced
pathophysiology and assessment; differential diagnosis and clinical management
across all body systems; pharmacotherapeutics; geriatric syndromes; professional
role competencies; and healthcare system navigation. Each question is crafted to
reflect the ANCC test content outline, emphasizing clinical reasoning, application of
guidelines, and patient-centered care across the lifespan. This resource features
100 multiple-choice questions with verified correct answers and detailed
rationales, designed to build confidence and ensure success on the AGPCNP
certification exam.
SECTION ONE: QUESTIONS 1–100
1. A 72-year-old male presents with a 3-month history of progressive exertional
dyspnea, orthopnea, and bilateral lower extremity edema. He reports
awakening at night gasping for air. His past medical history includes
hypertension and coronary artery disease. On examination, blood pressure is
148/92 mmHg, heart rate 88 bpm, jugular venous pressure is elevated at 12 cm
H₂O, and crackles are heard at the lung bases. An S₃ gallop is audible. Which
diagnostic test is most appropriate to confirm the suspected diagnosis?
• A. Chest X-ray
• B. Electrocardiogram
• C. Transthoracic echocardiogram
• D. Serum B-type natriuretic peptide (BNP)
, C. Transthoracic echocardiogram
RATIONALE: The patient presents with classic signs of heart failure with
reduced ejection fraction (HFrEF): exertional dyspnea, orthopnea, paroxysmal
nocturnal dyspnea, elevated JVP, S₃ gallop, and peripheral edema. While BNP can
support the diagnosis and chest X-ray can show pulmonary congestion, a
transthoracic echocardiogram is the gold standard for confirming heart failure,
assessing ejection fraction, and evaluating structural abnormalities.
Echocardiography provides essential information for guiding treatment decisions.
2. A 65-year-old female with type 2 diabetes mellitus, hypertension, and
hyperlipidemia presents for a routine follow-up. Her hemoglobin A1c is 7.6%,
blood pressure is 138/84 mmHg, and LDL cholesterol is 110 mg/dL. She is
currently on metformin 1000 mg twice daily, lisinopril 20 mg daily, and
atorvastatin 20 mg daily. According to the American Diabetes Association
(ADA) Standards of Care, which medication should be considered as add-on
therapy to reduce cardiovascular risk?
• A. Glipizide
• B. Pioglitazone
• C. Empagliflozin
• D. Insulin glargine
C. Empagliflozin
RATIONALE: The ADA Standards of Care recommend that patients with type 2
diabetes and established cardiovascular disease or high cardiovascular risk should
receive a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose
cotransporter-2 inhibitor (SGLT-2i) with demonstrated cardiovascular benefit,
regardless of A1c. Empagliflozin (an SGLT-2i) and liraglutide (a GLP-1 RA) have
shown cardiovascular risk reduction. Glipizide (sulfonylurea) and pioglitazone
, (thiazolidinedione) do not have proven cardiovascular benefit and carry other risks.
Insulin glargine does not provide cardiovascular risk reduction.
3. A 78-year-old male with moderate Alzheimer's disease is brought to the
clinic by his daughter. She reports that he has been increasingly forgetful,
agitated, and has had two episodes of wandering outside the home in the past
week. He is currently on donepezil 10 mg daily. Which of the following is the
most appropriate next step in management?
• A. Increase donepezil to 23 mg daily
• B. Add memantine
• C. Discontinue donepezil and start rivastigmine
• D. Prescribe an antipsychotic for agitation
B. Add memantine
RATIONALE: For patients with moderate to severe Alzheimer's disease, the
addition of memantine (an NMDA receptor antagonist) to a cholinesterase inhibitor
is recommended to improve cognition and functional outcomes. Donepezil at 23
mg daily is not well supported and is associated with more gastrointestinal side
effects without proven additional benefit. Switching cholinesterase inhibitors is not
indicated. Antipsychotics should be reserved for severe agitation or psychosis that
poses a safety risk, as they carry a black box warning for increased mortality in
elderly dementia patients.
4. A 55-year-old male with a 30-pack-year smoking history presents with a
chronic cough productive of mucoid sputum for the past 3 months, worse in the
mornings. He also reports progressive dyspnea on exertion. Spirometry reveals
an FEV1/FVC ratio of 0.62, FEV1 65% of predicted. Which of the following is the
most appropriate initial pharmacologic therapy for this patient?
• A. Inhaled corticosteroid (ICS) alone
TEST BANK | ANCC ADULT GERONTOLOGY
PRIMARY CARE NURSE PRACTITIONER
QUESTIONS AND CORRECT ANSWERS
(VERIFIED ANSWERS) PLUS RATIONALES
2025/2026 Q&A | INSTANT DOWNLOAD PDF
Core Domains:
• Health Promotion, Screening, and Disease Prevention
• Advanced Pathophysiology and Clinical Assessment
• Differential Diagnosis and Clinical Decision-Making
• Pharmacology and Medication Management
• Chronic Disease Management (Cardiovascular, Pulmonary, Endocrine,
Neurologic, Renal)
• Acute and Episodic Care
• Geriatric Syndromes and Frailty
• Professional Role, Ethics, and Healthcare Systems
• Cultural Competence and Health Equity
• Evidence-Based Practice and Quality Improvement
Introduction
,The AGPCNP ANCC (Adult-Gerontology Primary Care Nurse Practitioner)
certification examination is a rigorous assessment designed to validate the clinical
knowledge, critical thinking, and evidence-based decision-making skills required for
advanced practice nursing with young adult, adult, and older adult populations. This
comprehensive practice exam mirrors the content, format, and cognitive complexity
of the actual ANCC AGPCNP-BC board certification examination. The test bank
covers all major domains: health promotion and disease prevention; advanced
pathophysiology and assessment; differential diagnosis and clinical management
across all body systems; pharmacotherapeutics; geriatric syndromes; professional
role competencies; and healthcare system navigation. Each question is crafted to
reflect the ANCC test content outline, emphasizing clinical reasoning, application of
guidelines, and patient-centered care across the lifespan. This resource features
100 multiple-choice questions with verified correct answers and detailed
rationales, designed to build confidence and ensure success on the AGPCNP
certification exam.
SECTION ONE: QUESTIONS 1–100
1. A 72-year-old male presents with a 3-month history of progressive exertional
dyspnea, orthopnea, and bilateral lower extremity edema. He reports
awakening at night gasping for air. His past medical history includes
hypertension and coronary artery disease. On examination, blood pressure is
148/92 mmHg, heart rate 88 bpm, jugular venous pressure is elevated at 12 cm
H₂O, and crackles are heard at the lung bases. An S₃ gallop is audible. Which
diagnostic test is most appropriate to confirm the suspected diagnosis?
• A. Chest X-ray
• B. Electrocardiogram
• C. Transthoracic echocardiogram
• D. Serum B-type natriuretic peptide (BNP)
, C. Transthoracic echocardiogram
RATIONALE: The patient presents with classic signs of heart failure with
reduced ejection fraction (HFrEF): exertional dyspnea, orthopnea, paroxysmal
nocturnal dyspnea, elevated JVP, S₃ gallop, and peripheral edema. While BNP can
support the diagnosis and chest X-ray can show pulmonary congestion, a
transthoracic echocardiogram is the gold standard for confirming heart failure,
assessing ejection fraction, and evaluating structural abnormalities.
Echocardiography provides essential information for guiding treatment decisions.
2. A 65-year-old female with type 2 diabetes mellitus, hypertension, and
hyperlipidemia presents for a routine follow-up. Her hemoglobin A1c is 7.6%,
blood pressure is 138/84 mmHg, and LDL cholesterol is 110 mg/dL. She is
currently on metformin 1000 mg twice daily, lisinopril 20 mg daily, and
atorvastatin 20 mg daily. According to the American Diabetes Association
(ADA) Standards of Care, which medication should be considered as add-on
therapy to reduce cardiovascular risk?
• A. Glipizide
• B. Pioglitazone
• C. Empagliflozin
• D. Insulin glargine
C. Empagliflozin
RATIONALE: The ADA Standards of Care recommend that patients with type 2
diabetes and established cardiovascular disease or high cardiovascular risk should
receive a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose
cotransporter-2 inhibitor (SGLT-2i) with demonstrated cardiovascular benefit,
regardless of A1c. Empagliflozin (an SGLT-2i) and liraglutide (a GLP-1 RA) have
shown cardiovascular risk reduction. Glipizide (sulfonylurea) and pioglitazone
, (thiazolidinedione) do not have proven cardiovascular benefit and carry other risks.
Insulin glargine does not provide cardiovascular risk reduction.
3. A 78-year-old male with moderate Alzheimer's disease is brought to the
clinic by his daughter. She reports that he has been increasingly forgetful,
agitated, and has had two episodes of wandering outside the home in the past
week. He is currently on donepezil 10 mg daily. Which of the following is the
most appropriate next step in management?
• A. Increase donepezil to 23 mg daily
• B. Add memantine
• C. Discontinue donepezil and start rivastigmine
• D. Prescribe an antipsychotic for agitation
B. Add memantine
RATIONALE: For patients with moderate to severe Alzheimer's disease, the
addition of memantine (an NMDA receptor antagonist) to a cholinesterase inhibitor
is recommended to improve cognition and functional outcomes. Donepezil at 23
mg daily is not well supported and is associated with more gastrointestinal side
effects without proven additional benefit. Switching cholinesterase inhibitors is not
indicated. Antipsychotics should be reserved for severe agitation or psychosis that
poses a safety risk, as they carry a black box warning for increased mortality in
elderly dementia patients.
4. A 55-year-old male with a 30-pack-year smoking history presents with a
chronic cough productive of mucoid sputum for the past 3 months, worse in the
mornings. He also reports progressive dyspnea on exertion. Spirometry reveals
an FEV1/FVC ratio of 0.62, FEV1 65% of predicted. Which of the following is the
most appropriate initial pharmacologic therapy for this patient?
• A. Inhaled corticosteroid (ICS) alone
